Have questions or comments? Click here.
Last week the Food and Drug Administration (FDA) listened to presentations and comments from several members of an expert FDA advisory committee regarding the benefit-to-risk ratio of Long Acting Beta-agonist drugs (LABAs). The advisory panel consisted of 27 voting health care professionals representing subcommittees in pulmonary and allergy medicine, safety and risk, and pediatric advisory.
The medications of interest were LABAs prescribed for treatment... Read moreSo it's 6 a.m. and I'm driving down I-75 South in Georgia in the wee hours of the morning when the anxiety strikes. I couldn't find my... Read more »
Byetta and the long-acting release (LAR) formulation of that diabetes medication got most of the attention at the 66th Scientific Sessions... Read more »
The Paul Wellstone-Pete Domenici Mental Health Parity and Addiction Equity Act 2008 has passed both the House and Senate and was... Read more »
Recently, a brand new medication was approved for use in the United States by the Food & Drug Administration (FDA, for short). The... Read more »
I have good news for those of you who depended on Midrin for Migraines or tension-type headaches. I've confirmed that Macoven... Read more »
U.S. researchers have created a new, slow-release injectable nerve block that could be used as a long-lasting local anesthetic for the treatment of... Read more »
The U.S. Food and Drug Administration (FDA) has approved a sustained action form of the antipsychotic Invega for the treatment of schizophrenia.... Read more »
Drugmaker Eli Lilly is reporting that a long-acting formula of Zyprexa called Zyprexa Relprevv has been approved to treat schizophrenia in adults.... Read more »
According to Dr. Philip Lapp, injections remain the best option for diabetics who need long-acting or precise doses of insulin. Dr. Lapp explains how... Read more »
A panel that advises the U.S. Food and Drug Administration (FDA) about medications has found a long-acting, injectable form of Zyprexa 'acceptably... Read more »